DOMS Industries (DOMS) Q3 24/25 earnings summary

Executive summary

• Achieved strong revenue and profit growth in Q3 and 9M FY25, driven by expansion in stationery, art materials, and new product launches, as well as Uniclan Healthcare's positive contribution and new diaper production line.

• Recognized for export excellence with the Top Exporter Award for the third consecutive year by the Pen & Stationery Association of India.

• Launched ESOPs for over 900 employees, granted 117,045 stock options, and installed a 1MW solar plant to promote sustainability.

• Completed IPO in December 2023, raising net proceeds of ₹33,157.50 lakhs, with partial utilization and remaining funds invested in fixed deposits and monitoring accounts.

Financial highlights

• Q3 FY25 consolidated operating revenue: ₹50,111.38 lakhs (INR 501.1 crore), up 34.9% YoY; 9M FY25 revenue: ₹140,389.73 lakhs (INR 1,403.9 crore), up 23.9% YoY.

• Q3 FY25 EBITDA: ₹8,790 lakhs (INR 87.9 crore), up 26.7% YoY; EBITDA margin at 17.5%.

• Q3 FY25 PAT: ₹5,592.66 lakhs (INR 54.3 crore), up 40% YoY; 9M FY25 PAT: ₹16,225.64 lakhs (INR 162.3 crore), up 43.9% YoY.

• Basic and diluted EPS for Q3 FY25 were ₹8.94, compared to ₹6.88 in Q3 FY24.

• Comparable consolidated operating revenue (excluding Uniclan Healthcare) grew 21.4% YoY in Q3 FY25 and 18.2% in 9M FY25.

Outlook and guidance

• Maintains full-year consolidated revenue growth target of 23%-25%, including Uniclan; EBITDA margin guidance at 16%-17% due to Uniclan's lower margins and ESOP/capacity addition costs.

• Ongoing capacity expansion, modernization, and focus on omnichannel distribution and technology investments.

• Cautiously optimistic on demand, expecting tailwinds from back-to-school season and government spending; FY26 guidance to be finalized post-March business planning.

• Results for the current period are not fully comparable to previous periods due to recent acquisitions.